نقش پزشکی شخصی در تشخیص، پیشگیری و درمان بیماری‌هایی مانند کووید 19

نویسندگان

1 گروه شیمی، دانشکده فیزیک و شیمی، دانشگاه الزهرا، ونک، تهران، ایران

2 گروه شیمی، دانشکده فیزیک و شیمی، دانشگاه الزهرا، ونک، تهران، ایران.

3 دانشگاه علوم پزشکی مشهد، بیمارستان امام رضا، مشهد، ایران.

چکیده

پزشکی شخصی به مجموعه‌ای از فعالیت‌ها و رویکردهای تشخیصی، درمان و پیشگیری اطلاق می‌گردد که بر مبنای آن‌ها بیماران بر اساس ویژگی شخصی خود طبقه‌بندی شده و اقدامات پزشکی برایشان انجام می‌شود. اهدافی که سیستم درمانی با روش پزشکی شخصی به دنبال دارد شامل انتخاب یک داروی درست و مؤثر برای افراد مختلف، کاهش هزینه-های دارو و درمان، کاهش عوارض جانبی داروها و در نهایت کاهش مدت درمان و بهبودی سریع بیمار است. هدف مقاله حاضر بررسی اهمیت پزشکی شخصی، عواملی که باعث تفاوت افراد در پاسخ به درمان آن‌ها می‌شود، روش‌ها و تکنیک-های مورد استفاده برای رسیدن به اهداف پزشکی شخصی و در نهایت استفاده از این روش برای بررسی تفاوت‌های احتمالی افراد در پاسخ به درمان در برابر بیماری کووید 19 است. بر اساس این روش یا داروهایی که پیش از این ساخته شده‌اند برای هر فرد شخصی‌سازی می‌شود یا از داروهای پروتئینی نوترکیب استفاده می‌شود. بر اساس نوع عاملی که فرد را در پاسخ به درمان و دارو متفاوت کرده است نوع داروی مناسب و دوز لازم و کافی برای فرد تجویز می‌شود. با توجه به گزارش‌های موجود، در مورد بیماری کووید 19 نیز، تفاوت‌های ذکر شده در افراد مختلف می‌تواند در سیر رو به رشد بیماری موثر باشد و استفاده از رویکرد پزشکی شخصی منجر به معرفی روش درمانی ایمن، موثر و دقیق برای افراد مختلف شود. اما قطع به یقین می‌توان گفت مهم‌ترین هدفی که در پزشکی شخصی مطرح می‌شود پیشگیری است. به گونه‌ای که قبل از ابتلا به بیماری و تحمل درد و در نهایت تحمل عوارض جانبی داروهای مختلف برای درمان، احتمال وقوع بیماری با پایش مداوم نشان‌گرهای زیستی بیماری‌های مختلف که آن‌ها هم از طریق پزشکی شخصی مشخص شده-اند، در افراد سالم بررسی شود.

کلیدواژه‌ها

dor 20.1001.1.10272690.1399.30.79.8.5

عنوان مقاله [English]

The role of personal medicine in the diagnosis, prevention and treatment of diseases such as COVID-19

نویسندگان [English]

  • Zahra Talebpour 1
  • Marzieh Sourorishad 2
  • Hanieh Alizadeh 3
1 Department of Chemistry, Faculty of Physics and Chemistry, Alzahra University, Vanak, Tehran, Iran
2 Department of Chemistry, Faculty of Physics and Chemistry, Alzahra University, Sheikh Bahaei Sq, Tehran.
3 Mashhad University of Medical Science, Emam Reza Hospital, Mashhad, Iran.
چکیده [English]

Personalized medicine refers to a set of diagnostic, treatment, and prevention activities which classified patients based on their personal characteristics to tailor therapy with the best response. It is aimed to extend the One-Size-Fits-All approach to increase the ability to predict the most effective treatments for each individual, reduce financial and time expenditure, increase the life extension of patients, and the duration of treatment and recovery. This paper study the factors that differentiate individuals in response to treatment, and methods and techniques used to achieve personalized medicine purposes that discuss the importance of personal medicine. According to this approach, drugs are previously made will personalize for each individual or recombinant protein drugs will be used. According to the type of agent which make a difference between patients in response to treatment and drug, the appropriate drug type and necessary and sufficient dose prescribed for each patient. Based on the available report, in the case of Coronavirus disease-2019 (COVID-19), the differences mentioned in different people can be effective in the growing course of the disease and its treatment, and the use of personal medical approach will lead to the introduction of a safe, effective and accurate method for different people. The most important goals of personal medicine is prevention. So that in healthy individuals before the onset of illness, pain tolerance and finally the side effects of different drugs for the treatment of patient, personalized medicine will study the probability of occurrence of disease with continuous monitoring of biomarkers of different diseases.

کلیدواژه‌ها [English]

  • Human genome project
  • Mass spectrometry
  • Drug-protein binding
  • Drug interactions
  • Coronavirus disease-2019 (COVID-19)
Heather JM, Chain B. The sequence of sequencers: The history of sequencing DNA. Genomics. 2016; 107 (1): 1–8.
[2]   Company PR and M of A. Value of personalized medicine. Pharmaceutical Research and Manufacturers of America Company. (Report, 2015).
 
 
 
 
[3]   Ghorbani Parsa F, Hossein Pour Feizi M A. An overview of the second and third-generation of DNA sequencing technologies (Persian). Fasa University of Medical Sciences. 2018; 7 (4): 428–437.
[4]   International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004; 431 (7011): 931–945.
[5]   Sharma P, Das S, Biswas A. Story of gene: Part II – genetics and genomics. Practice of Cardiovascular Sciences. 2018; 4 (3): 224–232.
[6]   Erickson B. Human genome map turns 10. Chemical & Engineering News. 2013 20; 91 (20): 26–27.
[7]   Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583 (7816): 459–468.
[8]   Lopera Maya EA, van der Graaf A, Lanting P, van der Geest M, Fu J, Swertz M, et al. Lack of association between genetic variants at ACE2 and TMPRSS2 genes involved in SARS-CoV-2 infection and human quantitative phenotypes. Frontiers in Genetics. 2020; 11: 613.
[9]   Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?. Molecular Sciences. 2020; 21 (10): 3474.
[10]   Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367 (6483): 1260–1263.
[11]   Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012; 4 (6): 1011–1033.
[12]   Abbasi-Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings (Persian). Surgery. 2020; 79: 143–153.
[13]   Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. Cell Death Discov. 2020; 6 (1): 37.
[14]   Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020; 12 (11): 10087–10098.
[15]   Xu J-Y, Xu G-B, Chen S-L. A new method for SNP discovery. BioTechniques. 2009; 46 (3), 201–208
[16]   Yang S, Xu L, Wu HM. Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry. Molecular Diagnostics. 2010; 12 (2): 162–8.
[17]   Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978; 17 (8): 1371–7.
[18]   Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, et al. Aspirin resistance and a single gene. Cardiology. 2005; 95 (6): 805–8.
[19]   Ergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, et al. Impact of ABCB1 variants on neutrophil depression: A pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic & Clinical Pharmacology & Toxicology. 2012; 110 (2): 199–204.
[20]   Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, et al. Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2–positive breast cancer. JAMA Oncology. 2017; 3 (3): 335.
[21]   Lu N, Yang Y, Wang Y, Liu Y, Fu G, Chen D, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Molecular Biology Reports. 2012; 39 (6): 6581–9.
[22]   Pinheiro DS, Santos RS, Jardim PCBV, Silva EG, Reis AAS, Pedrino GR, et al. The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. PLOS ONE. 2019; 14 (8): e0221248.
[23]   Zhang Q, Cong M, Wang N, Li X, Zhang H, Zhang K, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender. Medicine. 2018; 97 (42): e12917.
[24]   Darbani B. The expression and polymorphism of entry machinery for COVID-19 in human: Juxtaposing population groups, gender, and different tissues. Environmental Research and Public Health. 2020; 17 (10): 3433.
[25]   Vuignier K, Guillarme D, Veuthey J-L, Carrupt P-A, Schappler J. High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug–plasma protein interactions. Pharmaceutical and Biomedical Analysis. 2013; 74: 205–12.
[26]   Li Z, Beeram SR, Bi C, Suresh D, Zheng X, Hage DS. [High-performance affinity chromatography: applications in drug-protein binding studies and personalized medicine]. 1 sted. United States of America: Academic Press Inc; 2016.
[27]   Yamasaki K, Chuang VTG, Maruyama T, Otagiri M. Albumin–drug interaction and its clinical implication. Biochimica et Biophysica Acta journal. 2013; 1830 (12): 5435–43.
[28]   Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Molecular Aspects of Medicine. 2012; 33 (3): 209–90.
[29]   Ali MA, Routh JI. The protein binding of acetylsalicylic acid and salicylic acid. Clin Chem. 1969; 15 (11): 1027–38.
[30]   Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. Molecular Biology. 2005; 353 (1): 38–52.
[31]   Zaidi N, Ahmad E, Rehan M, Rabbani G, Ajmal MR, Zaidi Y, et al. Biophysical insight into furosemide binding to human serum albumin: A study to unveil its impaired albumin binding in uremia. Physical Chemistry B. 2013; 117 (9): 2595–604.
[32]   Porgholami M. Pharmacokinetics and its importance in treatment (Persian). Razi journal of medical sciences. 1990; 1 (3): 34–40.
[33]   Bonnefoy J. Y. The biomarker revolution: a step toward personalized medicine. Personalized medicine. 2008; 5 (6): 553–6.
[34]   The Personalized Medicine Coalition (PMC). The personalized medicine report. PMC. (Report, 2017); 5-57.
[35]   Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics : The genetics of variable drug responses. Circulation. 2011; 123 (15): 1661–70.
[36]   U.S. Food and Drug Administration. Paving the way for personalized medicine. U.S. Food and Drug Administration & U.S. Department of Health and Human Services. (report, 2013); 1-60
[37]   Dingermann T. Recombinant therapeutic proteins: Production platforms and challenges. Biotechnology. 2008; 3 (1): 90–7.
[38]   Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nature Biotechnology. 2004; 22 (11): 1409–14.
[39]   Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnology Advances. 2012; 30 (5): 1102–7.
[40]   Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnology Advances. 2009; 27 (3): 297–306.
[41]   Srebalus Barnes CA, Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrometry Reviews. 2007; 26 (3): 370–88.
[42]   Zhang W, Marzilli LA, Rouse JC, Czupryn MJ. Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody. Analytical Biochemistry. 2002; 311 (1): 1–9.
[43]   Bai B, Lu X, Meng J, Hu Q, Mao P, Lu B, et al. Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses. Molecular Immunology. 2008; 45 (4): 868–75.
[44]   Cikach FS, Tonelli AR, Barnes J, Paschke K, Newman J, Grove D, et al. Breath analysis in pulmonary arterial hypertension. Chest. 2014; 145 (3): 551–8.
1. FS. Cikach
2. Pulmonary arterial hypertension (PAH)
3. Volatile organic compounds (VOCs)
4. Selected ion fow tube-mass spectrometry (SIFT-MS)